| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Nov―28 |
The role of the P2X7 receptor in inactivated SARS-CoV-2-induced lung injury |
N. C. Carvalho-Barbosa, Fabiana Cristina-Rodrigues, Jairo R. Temerozo, Thiago M. L. Souza, Andre L. Gouvêa, Claudio A. Canetti, Eleonora Kurtenbach, Dumith Chequer Bou-Habib, Claudia F. Benjamim, Christina M. Takiya, Luiz E. B. Savio, Robson Coutinho-Silva |
| 2 |
[GO] |
2024―Mar―09 |
Implications of COVID-19 in Parkinson’s disease: the purinergic system in a therapeutic-target perspective to diminish neurodegeneration |
Júlia Leão Batista Simões, Geórgia de Carvalho Braga, Samantha Webler Eichler, Gilnei Bruno da Silva, Margarete Dulce Bagatini |
| 3 |
[GO] |
2021―Nov―10 |
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling |
Djo Hasan, Atsuko Shono, Coenraad K. van Kalken, Peter J. van der Spek, Eric P. Krenning, Toru Kotani |
| 4 |
[GO] |
2021―May―10 |
Cystic fibrosis improves COVID-19 survival and provides clues for treatment of SARS-CoV-2 |
Edward H. Abraham, Guido Guidotti, Eliezer Rapaport, David Bower, Jack Brown, Robert J. Griffin, Andrew Donnelly, Ellen D. Waitzkin, Kenon Qamar, Mark A. Thompson, Sukumar Ethirajan, Kent Robinson |
| 5 |
[GO] |
2020―Jul―13 |
COVID-19 and purinergic signaling: the need for investigation |
Andréia Machado Cardoso |
|
